Abstract:

Objective To compare the clinical efficacy and safety differences between posaconazole and voriconazole for the prevention of fungal infections after allogeneic hematopoietic stem cell transplantation（allo ⁃ HSCT）. Methods Retrospective analysis of 104 patients（54 in the posaconazole group and 50 in the voricon⁃ azole group）who underwent allo ⁃ HSCT and applied posaconazole or voriconazole for fungal prophylaxis at our hospital from June 2019 to June 2021，comparing the incidence of IFI，the incidence of adverse drug reactions and other related indicators within 180 days after transplantation between the two groups. Results The incidence of IFI in the posaconazole and voriconazole groups was 7.4%（4 cases）and 20.0%（10 cases），respectively，with no statistical difference（P = 0.085）；in patients at high risk of IFI，the incidence of IFI in the two groups was 10.0% （3 cases）and 34.9%（9 cases），with a statistical difference（P = 0.047）；the incidence of adverse drug reactions in the two groups was 7.4%（4 cases）and 18.0%（9 cases），with no statistical difference（P = 0.091）. Conclusion Compared with voriconazole，posaconazole can further reduce the incidence of IFD in high⁃risk patients after trans⁃ plantation without increasing the incidence of drug⁃related adverse reactions. 

Key words:

allogeneic hematopoietic stem cell transplantation, invasive fungal infection, posacon? azole, voriconazole